STAAR Surgical traded at $17.76 this Friday February 20th, decreasing $0.12 or 0.67 percent since the previous trading session. Looking back, over the last four weeks, STAAR Surgical lost 13.83 percent. Over the last 12 months, its price rose by 5.28 percent. Looking ahead, we forecast STAAR Surgical to be priced at 17.21 by the end of this quarter and at 15.66 in one year, according to Trading Economics global macro models projections and analysts expectations.
STAAR Surgical Company is a developer, producer, and marketer of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company's principal products are implantable Collamer lenses (ICLs) and intraocular lenses (IOLs). ICLs, consists of the Company’s ICL family of products, including the Toric implantable Collamer lenses (TICL) and EVO+ Visian ICL, are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness), hyperopia (far-sightedness), astigmatism, and presbyopia. IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts, and include the Company’s lines of silicone IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). The Company sells its products in more than 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore.